NCT00525824 - 12-week Open-label, Phase IIIb Comparing Efficacy and Safety of Rosuvastatin (CRESTOR™) in Combination With Ezetimibe | Biotech Hunter

Enrollment

1,743

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

September 30, 2008

Study Completion Date

September 30, 2008

Conditions

HypercholesterolemiaCoronary Heart DiseaseAtherosclerosis

Interventions

DRUG

Rosuvastatin (Crestor)

10mg and 20 mg

DRUG

Ezetimibe

10 mg

DRUG

Simvastatin

40mg and 80 mg

Trial Locations (9)

Research Site, Brentwood

Research Site, Buenos Aires

Research Site, São Paulo

Research Site, Santiago

Research Site, Brentwood

Research Site, Zwinderen

Research Site, Lima

Research Site, Brentwood